www.fdanews.com/articles/123435-enzon-opens-a-phase-ii-study-of-peg-sn38-for-metastatic-breast-cancer

Enzon Opens a Phase II Study of PEG-SN38 for Metastatic Breast Cancer

January 6, 2010

Enzon Pharmaceuticals, Inc. Wednesday announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer.
Earth Times